Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases

Reuters01-13

<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases

Jasper Therapeutics Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603542792?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 01:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603542792","market":"fut","top_or_hot":-1,"title":"Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 01:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL96YnJH:1","article_id":"2603542792","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603542792","pubTimestamp":1768237364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jasper Therapeutics Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","JSPR":"Jasper Therapeutics"},"translate_title":"Jasper Therapeutics展示了Briquilimab在炎症性疾病靶向肥大细胞耗竭方面的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JSPR":0.9},"content_text":"Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases\n    \n\n        Jasper Therapeutics Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603542792","isCrawlerRequest":true}